X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor, which is being evaluated for the treatment of PTSD and Social Anxiety Disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Details:
BNC210 is a negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor under development for the treatment of social anxiety disorder and post-traumatic stress disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
BNC210 is a negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2023
Details:
Under the collaboration, MK-4334, a novel clinical candidate was developed by MSD and derived from Bionomics’ original α7 nAChR PAM candidate (BNC375) for the treatment of cognitive disorders like Alzheimer’s Disease.
Lead Product(s): MK-4334,Donepepzil
Therapeutic Area: Neurology Product Name: MK-4334
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $526.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration September 14, 2023
Details:
BNC210 is a negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2023
Details:
BNC210 is a negative allosteric modulator of the α7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2023
Details:
BNC210 has a novel mechanism of action that involves negative allosteric modulation of the α7 nicotinic acetylcholine receptor. The Company is continuing analysis of the PREVAIL dataset and is assessing next steps for the development of BNC210 in SAD.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
BNC210 is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (PTSD).
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aegis Capital Corp.
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 21, 2022
Details:
The primary objective of Phase 2 PREVAIL Study is to compare each dose level of BNC210 to placebo, and secondary objectives include two other scales measuring participants' anxiety levels. BNC210 is α7 nicotinic acetylcholine receptor modulator used for acute treatment of SAD.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2022
Details:
BNC210 is an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor in development for the acute treatment of SAD and chronic treatment of PTSD. The PREVAIL Study remains on target to initiate by end of 2021.
Lead Product(s): BNC210
Therapeutic Area: Psychiatry/Psychology Product Name: BNC210
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
